| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development expenses | $14.5M+45.3% | $10.0M-9.9% | $11.1M+24.4% | $8.9M+155.5% | $3.5M |
| General and administrative expenses | $9.7M+39.9% | $6.9M-23.4% | $9.1M+47.6% | $6.1M+43.2% | $4.3M |
| Total operating expenses | $24.3M+43.1% | $17.0M-16.0% | $20.2M+24.8% | $16.2M+107.7% | $7.8M |
| Loss from operations | -$24.3M-43.1% | -$17.0M+16.0% | -$20.2M-24.8% | -$16.2M-107.7% | -$7.8M |
| Interest expense | -$57 | — | -$7K+1.5% | -$7K+99.2% | -$828K |
| Interest income | $314K-1.4% | $318K+823.1% | $34K+1744.4% | $2K-7.1% | $2K |
| Australian research and development incentives | $80K | — | $177K-43.7% | $314K+618.2% | $44K |
| Grant income | $361K | — | — | — | — |
| Change in fair value of warrant liability | $1.2M+117.9% | -$6.7M-3357.8% | $205K+108.5% | $98K+106.4% | -$1.5M |
| Loss on fair value of warrants over proceeds | -$13K | — | — | — | — |
| Other income (expense) net: | $1.9M+129.8% | -$6.3M-1637.9% | $409K+0.6% | $407K+108.5% | -$4.8M |
| Net loss | -$22.4M+3.7% | -$23.3M-17.6% | -$19.8M-25.4% | -$15.8M-25.4% | -$12.6M |
| Net loss per share - basic | -$0.70+33.3% | -$1.05+29.5% | -$1.49+14.9% | -$1.75+26.2% | -$2.37 |
| Net loss per share - diluted | -$0.70+33.3% | -$1.05+29.5% | -$1.49+14.9% | -$1.75+26.2% | -$2.37 |
| Weighted average common shares outstanding - basic | 32.1M+44.7% | 22.2M+67.4% | 13.3M+43.0% | 9.3M+75.7% | 5.3M |
| Weighted average common shares outstanding - diluted | 32.1M+44.7% | 22.2M+67.4% | 13.3M+43.0% | 9.3M+75.7% | 5.3M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.